Koji Ogawa
Sapporo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 108 publications
Reply to "Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?"
Journal: Journal of gastroenterology
Published: August 17, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.
Journal: The Journal of infection
Published: November 21, 2025
Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan.
Journal: Journal of gastroenterology
Published: November 09, 2025
Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.
Journal: Hepatology international
Published: October 22, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.
Journal: Scientific reports
Published: September 19, 2025
Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug-Induced Liver Injury.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 09, 2025
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 30, 2025
Impact of preoperative NAFLD status on restoration of pancreatic β-cell function after laparoscopic sleeve gastrectomy.
Journal: American journal of physiology. Endocrinology and metabolism
Published: May 16, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Journal: Hepatology international
Published: April 30, 2025
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Journal: Targeted oncology
Published: August 14, 2024
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.
Journal: JHEP reports : innovation in hepatology
Published: August 04, 2024
Last Updated: 09/26/2026